Lilly eyes Zepbound label expansion after clearing phase III sleep apnea study

With Wednesday’s readout showing symptom improvements in obstructive sleep apnea patients, Eli Lilly is preparing to file for a label expansion for its top-selling weight-loss drug Zepbound.